4536 Stock Overview
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally.
Santen Pharmaceutical Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||JP¥1,058.00|
|52 Week High||JP¥1,718.00|
|52 Week Low||JP¥968.00|
|1 Month Change||-1.86%|
|3 Month Change||-1.58%|
|1 Year Change||-28.99%|
|3 Year Change||-41.25%|
|5 Year Change||-37.98%|
|Change since IPO||242.03%|
Recent News & Updates
|4536||JP Pharmaceuticals||JP Market|
Return vs Industry: 4536 underperformed the JP Pharmaceuticals industry which returned 6% over the past year.
Return vs Market: 4536 underperformed the JP Market which returned -0.1% over the past year.
|4536 Average Weekly Movement||3.4%|
|Pharmaceuticals Industry Average Movement||4.1%|
|Market Average Movement||3.9%|
|10% most volatile stocks in JP Market||8.1%|
|10% least volatile stocks in JP Market||2.1%|
Stable Share Price: 4536 is not significantly more volatile than the rest of JP stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: 4536's weekly volatility (3%) has been stable over the past year.
About the Company
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis.
Santen Pharmaceutical Fundamentals Summary
|4536 fundamental statistics|
Is 4536 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|4536 income statement (TTM)|
|Cost of Revenue||JP¥111.15b|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||67.48|
|Net Profit Margin||9.95%|
How did 4536 perform over the long term?See historical performance and comparison
3.0%Current Dividend Yield
Does 4536 pay a reliable dividends?See 4536 dividend history and benchmarks
|Santen Pharmaceutical dividend dates|
|Ex Dividend Date||Sep 29 2022|
|Dividend Pay Date||Nov 30 2022|
|Days until Ex dividend||52 days|
|Days until Dividend pay date||114 days|
Does 4536 pay a reliable dividends?See 4536 dividend history and benchmarks
Is 4536 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4536?
Other financial metrics that can be useful for relative valuation.
|What is 4536's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 4536's PE Ratio compare to its peers?
|4536 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
4506 Sumitomo Pharma
4581 Taisho Pharmaceutical Holdings
4516 Nippon Shinyaku
4536 Santen Pharmaceutical
Price-To-Earnings vs Peers: 4536 is good value based on its Price-To-Earnings Ratio (15.7x) compared to the peer average (15.8x).
Price to Earnings Ratio vs Industry
How does 4536's PE Ratio compare vs other companies in the JP Pharmaceuticals Industry?
Price-To-Earnings vs Industry: 4536 is good value based on its Price-To-Earnings Ratio (15.7x) compared to the JP Pharmaceuticals industry average (17.4x)
Price to Earnings Ratio vs Fair Ratio
What is 4536's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||15.7x|
|Fair PE Ratio||19.6x|
Price-To-Earnings vs Fair Ratio: 4536 is good value based on its Price-To-Earnings Ratio (15.7x) compared to the estimated Fair Price-To-Earnings Ratio (19.6x).
Share Price vs Fair Value
What is the Fair Price of 4536 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 4536 (¥1058) is trading below our estimate of fair value (¥1643.78)
Significantly Below Fair Value: 4536 is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
How is Santen Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4536's forecast earnings growth (3.7% per year) is above the savings rate (0.04%).
Earnings vs Market: 4536's earnings (3.7% per year) are forecast to grow slower than the JP market (8.6% per year).
High Growth Earnings: 4536's earnings are forecast to grow, but not significantly.
Revenue vs Market: 4536's revenue is expected to decline over the next 3 years (-1.3% per year).
High Growth Revenue: 4536's revenue is forecast to decline over the next 3 years (-1.3% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 4536's Return on Equity is forecast to be low in 3 years time (7.1%).
Discover growth companies
How has Santen Pharmaceutical performed over the past 5 years?
Past Performance Score4/6
Past Performance Score 4/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 4536 has high quality earnings.
Growing Profit Margin: 4536's current net profit margins (9.9%) are higher than last year (3.1%).
Past Earnings Growth Analysis
Earnings Trend: 4536's earnings have declined by 15.5% per year over the past 5 years.
Accelerating Growth: 4536's earnings growth over the past year (232.6%) exceeds its 5-year average (-15.5% per year).
Earnings vs Industry: 4536 earnings growth over the past year (232.6%) exceeded the Pharmaceuticals industry 17.2%.
Return on Equity
High ROE: 4536's Return on Equity (7.7%) is considered low.
Discover strong past performing companies
How is Santen Pharmaceutical's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 4536's short term assets (¥218.7B) exceed its short term liabilities (¥88.1B).
Long Term Liabilities: 4536's short term assets (¥218.7B) exceed its long term liabilities (¥30.3B).
Debt to Equity History and Analysis
Debt Level: 4536 is debt free.
Reducing Debt: 4536 had no debt 5 years ago.
Debt Coverage: 4536 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 4536 has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies
What is Santen Pharmaceutical current dividend yield, its reliability and sustainability?
Dividend Score 4/6
Cash Flow Coverage
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: 4536's dividend (3.02%) is higher than the bottom 25% of dividend payers in the JP market (1.63%).
High Dividend: 4536's dividend (3.02%) is low compared to the top 25% of dividend payers in the JP market (3.62%).
Stability and Growth of Payments
Stable Dividend: 4536's dividends per share have been stable in the past 10 years.
Growing Dividend: 4536's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (48.1%), 4536's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its high cash payout ratio (146.8%), 4536's dividend payments are not well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Shigeo Taniuchi (49 yo)
Mr. Shigeo Taniuchi has been President of Santen Pharmaceutical Co., Ltd. since April 1, 2018 and serves as its Chief Executive Officer since April 01, 2020 and served as Head of Human Resources Division u...
CEO Compensation Analysis
Compensation vs Market: Insufficient data to establish whether Shigeo's total compensation is reasonable compared to companies of similar size in the JP market.
Compensation vs Earnings: Insufficient data to compare Shigeo's compensation with company performance.
Experienced Management: 4536's management team is considered experienced (2.1 years average tenure).
Experienced Board: 4536's board of directors are considered experienced (3.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Santen Pharmaceutical Co., Ltd.'s employee growth, exchange listings and data sources
- Name: Santen Pharmaceutical Co., Ltd.
- Ticker: 4536
- Exchange: TSE
- Founded: 1890
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: JP¥415.983b
- Shares outstanding: 393.18m
- Website: https://www.santen.com
Number of Employees
- Santen Pharmaceutical Co., Ltd.
- Grand Front Osaka Tower A
- 4-20 Ofuka-cho
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/07 00:00|
|End of Day Share Price||2022/08/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.